6,709 Shares in Evolent Health, Inc. (NYSE:EVH) Bought by Xponance Inc.

Xponance Inc. purchased a new position in shares of Evolent Health, Inc. (NYSE:EVH) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 6,709 shares of the technology company’s stock, valued at approximately $222,000.

Several other institutional investors have also bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Evolent Health by 12.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,355 shares of the technology company’s stock worth $771,000 after buying an additional 2,677 shares in the last quarter. Mackenzie Financial Corp bought a new stake in Evolent Health during the fourth quarter worth $236,000. Strs Ohio grew its holdings in Evolent Health by 46.3% during the fourth quarter. Strs Ohio now owns 6,000 shares of the technology company’s stock worth $198,000 after buying an additional 1,900 shares in the last quarter. Genesee Capital Advisors LLC grew its holdings in Evolent Health by 2.2% during the fourth quarter. Genesee Capital Advisors LLC now owns 38,390 shares of the technology company’s stock worth $1,268,000 after buying an additional 825 shares in the last quarter. Finally, HB Wealth Management LLC bought a new stake in Evolent Health during the fourth quarter worth $1,425,000.

Analysts Set New Price Targets

EVH has been the subject of several recent research reports. JMP Securities upped their price target on Evolent Health from $37.00 to $38.00 and gave the stock a “market outperform” rating in a report on Friday, February 23rd. JPMorgan Chase & Co. cut their price objective on Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a research report on Friday, March 15th. Canaccord Genuity Group cut their price objective on Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, March 28th. Oppenheimer started coverage on Evolent Health in a research report on Friday, March 1st. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Barclays started coverage on Evolent Health in a research report on Wednesday, January 3rd. They issued an “overweight” rating and a $39.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.70.

Evolent Health Stock Down 2.4 %

Shares of NYSE EVH opened at $27.65 on Friday. Evolent Health, Inc. has a one year low of $23.33 and a one year high of $36.70. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.01 and a quick ratio of 1.01. The business’s fifty day moving average price is $31.77 and its 200-day moving average price is $30.28. The stock has a market capitalization of $3.19 billion, a PE ratio of -21.77 and a beta of 1.53.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, February 22nd. The technology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.13. Evolent Health had a positive return on equity of 6.60% and a negative net margin of 5.76%. The firm had revenue of $556.06 million for the quarter, compared to analysts’ expectations of $541.87 million. On average, equities research analysts anticipate that Evolent Health, Inc. will post 0.87 EPS for the current year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.